NEUROHK s r o

Running trials

• Enrolling by invitation

  An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

  NCT07459660· Phase 2· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Phase 3· Source

• Recruiting

  A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  NCT06937229· Phase 3· Source

• Recruiting

  Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

  NCT07095465· Phase 3· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

  NCT06887192· Phase 2· Source

• Recruiting

  Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

  NCT07029581· Phase 2· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

  NCT07011745· Phase 3· Source

• Recruiting

  A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

  NCT06976268· Phase 2/3· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

  NCT06651567· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

  NCT06625060· Phase 2· Source

• Enrolling by invitation

  ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

  NCT06194799· Phase 3· Source

• Active, not recruiting

  A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.

  2022-501622-37-00· Phase 3· Source

• Active, not recruiting

  Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

  NCT05531526· Phase 3· Source

• Active, not recruiting

  A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease

  NCT02726386· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease6 recruiting
• Lewy body dementia2 recruiting
• Multiple sclerosis2 recruiting
• Schizophrenia2 recruiting
• Parkinson disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Active, not recruiting

  Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

  NCT06806293· Phase 3· Source

• Completed

  Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

  NCT06241313· Phase 3· Source

• Recruiting

  ACP-204 in Adults With Alzheimer's Disease Psychosis

  NCT06159673· Phase 2/3· Source

• Completed

  Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine

  NCT05748483· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

  NCT06047457· Phase 3· Source

• Completed

  Open-label Trial in Parkinson's Disease (PD)

  NCT04760769· Phase 3· Source

• Completed

  A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

  NCT04686136· Phase 3· Source